Monoclonal antibodies targeting PD-1/PD-L1 are being extensively used in a wide range of solid tumour types, including melanoma, non-small cell lung cancer, squamous cell cancer of head and neck, bladder cancer, renal cell carcinoma, as well as haematological malignancies, particularly, aggressive B-cell lymphomas and multiple myeloma [7]. The gene discussed is CD274; the disease is melanoma.